Education
About Us
Working with TipRanks
Follow Us
MiMedx Group (MDXG)
NASDAQ:MDXG
MDXG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.47 - $10.14
Previous CloseN/A
Volume99.42K
Average Volume (3M)543.46K
Market Cap
$1.24B
Enterprise Value$807.11M
Total Cash (Recent Filing)$45.12M
Total Debt (Recent Filing)$2.05M
Price to Earnings (P/E)29.5
Beta0.81
Next Earnings
May 06, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding147,366,060
10 Day Avg. Volume589,289
30 Day Avg. Volume543,464
Standard Deviation0.20
R-Squared0.26
Alpha0.00093
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.44
Price to Cash Flow (P/CF)16.00
P/FCF Ratio14.70
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.02
Enterprise Value/Ebitda12.24
Forecast
1Y Price Target
$12.50Price Target Upside48.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
MiMedx Group News
PremiumCompany Announcements
MiMedx Earnings Call: Growth Amidst Challenges
PremiumCompany Announcements
MiMedx Group Reports Strong 2024 Financial Results
PremiumCompany Announcements
MiMedx Group Reports Strong 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Product Approval And Market ShareMiMedx Group's status as a good actor with strong products on approved Skin Substitute lists is expected to drive market share growth.
Strategic InitiativesManagement remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.
Bears Say
Reimbursement UncertaintyContinuing reimbursement uncertainty disrupted the business in the physician office setting.
---
Ownership Overview
1.68% Insiders
10.11% Mutual Funds
34.82% Other Institutional Investors
43.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MDXG FAQ
What was MiMedx Group’s price range in the past 12 months?
MiMedx Group lowest stock price was $5.47 and its highest was $10.14 in the past 12 months.
What is MiMedx Group’s market cap?
MiMedx Group’s market cap is $1.24B.
When is MiMedx Group’s upcoming earnings report date?
MiMedx Group’s upcoming earnings report date is May 06, 2025 which is in 63 days.
How were MiMedx Group’s earnings last quarter?
MiMedx Group released its earnings results on Feb 26, 2025. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.072 by -$0.022.
Is MiMedx Group overvalued?
According to Wall Street analysts MiMedx Group’s price is currently Undervalued.
Does MiMedx Group pay dividends?
MiMedx Group does not currently pay dividends.
What is MiMedx Group’s EPS estimate?
MiMedx Group’s EPS estimate is 0.05.
How many shares outstanding does MiMedx Group have?
MiMedx Group has 147,366,060 shares outstanding.
What happened to MiMedx Group’s price movement after its last earnings report?
MiMedx Group reported an EPS of $0.05 in its last earnings report, missing expectations of $0.072. Following the earnings report the stock price went up 1.623%.
Which hedge fund is a major shareholder of MiMedx Group?
Currently, no hedge funds are holding shares in MDXG
---
MiMedx Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (48.81% Upside)
$12.50 (48.81% Upside)
Blogger Sentiment
Bullish
MDXG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 137.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.50%
12-Months-Change
Fundamentals
Return on Equity
25.01%
Trailing 12-Months
Asset Growth
10.40%
Trailing 12-Months
Company Description
MiMedx Group
MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.
---
MDXG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, a solid cash position, and successful international expansion. However, challenges related to Medicare reimbursement and potential market disruption due to new LCD implementations were noted. Legal and regulatory issues also present ongoing challenges.Read More>---
MDXG Stock 12 Month Forecast
Average Price Target
$12.50
▲(48.81% Upside)
Technical Analysis
Apyx Medical
―
Orasure Technologies
―
T2 Biosystems
―
Iterum Therapeutics
―
Journey Medical Corp
―
Best Analysts Covering MDXG
1 Year
1 Year Success Rate
10/11 ratings generated profit
1 Year Average Return
+61.80%
reiterated a buy rating 10 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +61.80% per trade.
---